Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05427864

Enrollment

Registered

2022-06-22

Start date

2020-01-01

Completion date

2023-03-05

Last updated

2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer, Prostate Cancer Stage

Brief summary

In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.

Interventions

DIAGNOSTIC_TESTMultiparametric Prostate MRI

Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

47 male patients who will be evaluated with both imaging studies will be included in the study.

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* diagnosed with prostate cancer * Gleason score 7 or above / 6 with high risk * No other treatment

Exclusion criteria

* treated with radiotherapy * treated with ADT

Design outcomes

Primary

Measure	Time frame	Description
Lesion location	Between prostate biopsy and curative treatment decision , usually 2 month	Both MRI and PET results will be compared. Lesion location will be defined as left, right, apical, basal, midline.
Lesion Size	Between prostate biopsy and curative treatment decision , usually 2 month	Both MRI and PET results will be compared, Lesion size will be stated in milimeters.
Lymph node involvement	Between prostate biopsy and curative treatment decision , usually 2 month	Both MRI and PET results will be compared. Involvement will be stated as exist, non-exist.
Extraprostatic involvement	Between prostate biopsy and curative treatment decision , usually 2 month	Both MRI and PET results will be compared. Involvement will be stated as exist , non-exist.
Local and distant metastasis	Between prostate biopsy and curative treatment decision , usually 2 month	Both MRI and PET results will be compared. Metastasis will be stated as exist , non-exist.

Countries

Turkey (Türkiye)

Contacts

Primary ContactCan Sicimli, M.D.

cansicimli@gmail.com+905077287879

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026